Across TCGA pan-cancer cohorts, MIR944 RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of MIR944’s most consistent transcriptional readouts.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where MIR944 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MIR944 is over-expressed in tumor.
HNSC are the cancer types where MIR944 tumor–normal differential expression is most reproducible.